• Publications
  • Influence
Effect of the inosine 5'-monophosphate dehydrogenase inhibitor BMS-566419 on rat cardiac allograft rejection.
TLDR
The results suggest that BMS-566419 and other chemically synthesized IMPDH inhibitors have beneficial pharmacological effects similar to those of MMF, and are potential pharmaceutical candidates in transplant indications. Expand
Effect of the immunosuppressant histone deacetylase inhibitor FR276457 in a canine renal transplant model.
TLDR
The HDAC inhibitor FR276457 inhibited the proliferation of T cell line established from human in vitro and clinically prolonged allograft survival when administered as a monotherapy, and had additive or synergistic effects when combined with tacrolimus with the canine renal transplant model. Expand
Efficacy of oral treatment with tacrolimus in the renal transplant model in cynomolgus monkeys.
TLDR
2.0 mg/kg was considered to be a therapeutic dose in this model, and 0.5 or 1.0mg/kg could be used for a study when efficacy of a new compound is evaluated in a combination therapy with tacrolimus. Expand
In vitro and in vivo characterization of AS2643361, a novel and highly potent inosine 5'-monophosphate dehydrogenase inhibitor.
TLDR
Results suggest AS2643361 has higher potency and less toxicity than MMF, making it a potential candidate for treatment of acute and chronic rejection in transplant medicine. Expand
Effect of the inosine 5'-monophosphate dehydrogenase inhibitor BMS-566419 on renal fibrosis in unilateral ureteral obstruction in rats.
TLDR
Evaluated the antifibrotic effects of BMS-566419 using an experimental rat model, unilateral ureteral obstruction, and other chemically synthesized IMPDH inhibitors have beneficial pharmacological effects similar to those of MMF, and are potential pharmaceutical candidates in the treatment of fibrotic renal disease, including CAN. Expand
A chronic renal rejection model with a fully MHC-mismatched rat strain combination under immunosuppressive therapy.
TLDR
It is suggested that this rat model of chronic rejection using fully MHC-mismatched strains in which kidney disease progresses even under immunosuppressive therapy more accurately reflects transplantation in a clinical setting than existing models and enables the evaluation of therapeutic agents. Expand
Absence of Activation-induced Cytidine Deaminase, a Regulator of Class Switch Recombination and Hypermutation in B Cells, Suppresses Aorta Allograft Vasculopathy in Mice
TLDR
It is shown that AID deficiency in mice enables suppression of allograft vasculopathy (AV) after aorta transplantation, a DSA-mediated process, and proposed that AIDs could be a novel molecular target for controlling antibody-mediated rejection in organ transplantation. Expand
Replacement of mycophenolate mofetil with a JAK inhibitor, AS2553627, in combination with low‐dose tacrolimus, for renal allograft rejection in non‐human primates
TLDR
It is suggested that AS2553627 replacing MMF in combination with a sub‐therapeutic dose of TAC to treat allograft rejection in a monkey model is an attractive CNI‐sparing strategy to prevent renal allografted rejection. Expand
Prevention of chronic renal allograft rejection by AS2553627, a novel JAK inhibitor, in a rat transplantation model.
TLDR
Results indicate the therapeutic potential of JAK inhibitors in chronic rejection progression, and suggest that AS2553627 is a promising agent to improve long-term graft survival after renal transplantation. Expand
Mechanism Analysis of Long-Term Graft Survival by Monocarboxylate Transporter-1 Inhibition
TLDR
The data suggest that the mechanism of AS2495674 involves generating a tolerogenic graft environment by preferentially targeting T effector cells while sparing the generation of T regulatory cells. Expand